Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Syndax Pharmaceuticals Inc. has disclosed extended purine tricyclic and bicyclic nucleosides as prodrugs reported to be useful for the treatment of viral infections.

Roche’s recent spate of billion-dollar plus alliances has continued with a deal with UK biotech Bicycle Therapeutics – worth up to $1.7 billion – in the area of cancer immunotherapy.

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Chengdu Tetrahedral Drug Research Co. Ltd. has synthesized bicyclic derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infection.